Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
暂无分享,去创建一个
H. Ortega | S. Wenzel | C. Prazma | B. Hartley | N. Barnes | J. Douglass
[1] W. Busse,et al. Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program. , 2014, The Journal of allergy and clinical immunology.
[2] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[3] Parameswaran Nair,et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.